31720-89-5

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 5-ACETOXYINDOLE-2-CARBOXYLATE is used as an intermediate in the synthesis of bioactive molecules for the development of new drugs. Its role in creating antineoplastic and anti-inflammatory agents makes it a valuable component in the formulation of medications targeting various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 5-ACETOXYINDOLE-2-CARBOXYLATE is utilized as a building block for the preparation of new functional materials. Its properties and reactivity contribute to the development of innovative agrochemical products, enhancing crop protection and management strategies.
Used in Research and Development:
ETHYL 5-ACETOXYINDOLE-2-CARBOXYLATE is used as a research compound by chemists and researchers in various fields. Its unique properties and potential applications make it an interesting subject for scientific exploration and the development of novel applications in both pharmaceutical and agrochemical industries.

InChI:InChI=1/C13H13NO4/c1-3-17-13(16)12-7-9-6-10(18-8(2)15)4-5-11(9)14-12/h4-7,14H,3H2,1-2H3

Upstream product

• 108-24-7 acetic anhydride 
• 24985-85-1 ethyl 5-hydroxyindole-2-carboxylate 
• 303052-47-3 ethyl 3-benzyloxyindole-2-carboxylate 

Downstream Products

• 287714-94-7 ethyl 5-acetoxy-N-(3,4-dichlorobenzyl)indole-2-carboxylate 
• 350589-08-1 ethyl N-(3-methoxy-4-chlorobenzyl)-5-acetoxyindole-2-carboxylate 

Relevant academic research and scientific papers

Indole derivatives as MCP-1 receptor antagonists

A compound of Formula I, wherein: R1 is hydrogen, halo, methyl, ethyl or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group, lower alkyl, lower alkenyl, lower alkynyl, alkoxy, trifluoromethyl, nitro, cyano, trifluoromethoxy, C(O)R7, or S(O)nR7 where n is 0, 1 or 2 and R7 is an alkyl group; R4 is a halo, trifluoromethyl, methylthio, methoxy, trifluoromethoxy or lower alkyl, lower alkenyl or lower alkynyl or COR8 where R8 is lower alkyl; R6 is hydrogen, halo, lower alkyl, lower alkenyl, lower alkynyl or COR9 where R9 is lower alkyl; provided that when R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy, R5 and R6 are both hydrogen, and one of R3 or R4 is not halo or trifluoromethyl; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonizing an MCP-1 mediated effect in a warm-blooded animal such as a human being.

Indole derivatives and their use as MCP-1 antagonist

A compound of formula (1) wherein R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is carboxy, tetrazolyl, or —CONHSO2R4where R4is methyl, ethyl, phenyl, 2,5-dimethylisoxazolyl or trifluoromethyl; T is —CH2— or —SO2—; and ring A is 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl; or a pharmaceutically acceptable salt or prodrug thereof, as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.

Indole derivatives as mcp-1 receptor antagonists

A compound of formula (I) wherein: R1 is hydrogen, halo or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is a halo group or a trifluoromethyl group; R4 is a halo group or a trifluoromethyl group; R5 is hydrogen or halo; R6 is hydrogen or halo; provided that when R5 and R6 are both hydrogen, and one of R3 or R4 is chloro or fluoro, then the other is not chloro or fluoro; or a pharmaceutically acceptable salt or prodrug thereof. These compounds have useful activity for the treatment of inflammatory disease, specifically in antagonising an MCP-1 mediated effect in a warm-blooded animal such as a human being.